The introduction of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable interest within the healthcare community. This novel dual GIP and GLP-1 target medication suggests to offer impressive improvements in fat loss compared to existing therapies. Initial patient data have shown marked declines in weight , conceivably marking a new p